The Efficacy of Melissa Officinalis and Nepeta Menthoides Combination on Insomnia

The Comparison of The Efficacy of Melissa Officinalis and Nepeta Menthoides (Boiss & Buhse) Combination versus Placebo on Insomnia

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015040621592N2

Enrollment

Registered

2015-05-03

Start date

2015-04-09

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Insomnia. Condition 2: Generalized anxiety disorder. Condition 3: Depression. Condition 4: Insomnia. Non organic sleep disorders Generalized anxiety disorder Depressive episode Nonorganic sleep disorder, unspecified

Interventions

Intervention 1: Three 500 mg placebo capsules 2 hours before usual sleep time at night. Intervention 2: Three 500 mg capsules of Melissa officinalis and Nepeta Menthoides combination 2 hours before us

Placebo

Treatment - Drugs

Three 500 mg placebo capsules 2 hours before usual sleep time at night

Three 500 mg capsules of Melissa officinalis and Nepeta Menthoides combination 2 hours before usual sleep time at night

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: Over 18 year old patients with the diagnosis of insomnia without using allopathic sleep aid medication; Patients with the oral or written informed consent; ISI Score>7 Exclusion critria: Patients with uncontrolled and severe organic or psychiatric diseases and pain disorders which cause insomnia directly or by their treatment ;pregnancy and lactation; alchohol or substance abuse; thyriod disase; any other medication use or their withdrawal which affects sleep; other sleep disorders; history of sever drug reaction to Melissa Off or Nepeta Menthoides

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Insomnia. Timepoint: Baseline,second and 4th week. Method of measurement: ,SLEEP LOG.;Depression. Timepoint: Baseline and second and 4th week. Method of measurement: Beck depression inventory.;Generalized anxiety disorder. Timepoint: Baseline and second ,4th week. Method of measurement: Beck anxiety inventory.	—

Secondary

Measure	Time frame
Side effects like unusual drug reaction, gi discomfort. Timepoint: During the clinical trial specially on the second ,4th week. Method of measurement: By asking the patient.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Ranjbar

Shiraz University of Medical Sciences

dr.mranjbar@yahoo.com+98 21667541515

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026